NMC
AVTX icon

NEA Management Company’s Avalo Therapeutics AVTX Stock Holding History

NEA Management Company’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-207
Closed -$506K – 44
2017
Q3 		$506K Hold
207
– – 0.02% 43
2017
Q2 		$341K Hold
207
– – 0.01% 43
2017
Q1 		$402K Hold
207
– – 0.01% 38
2016
Q4 		$524K Hold
207
– – 0.02% 38
2016
Q3 		$2.52M Hold
207
– – 0.11% 32
2016
Q2 		$1.31M Hold
207
– – 0.07% 36
2016
Q1 		$2.22M Hold
207
– – 0.15% 33
2015
Q4 		$1.2M Buy
+207
New +$2.27M 0.08% 34

Other funds holding AVTX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

NEA Management Company's AVTX Position: Q4 2017 in Review

NEA Management Company sold out of Avalo Therapeutics (AVTX) in Q4 2017, closing a stake of 207 shares — an estimated $506K sold.

NEA Management Company first reported a position in AVTX in Q4 2015 and held it in 8 quarters. The position peaked at $2.52M in Q3 2016. 16 funds tracked by Wall St. Rank hold AVTX as of Q4 2017.

  • NEA Management Company reported no remaining Avalo Therapeutics position as of Q4 2017 after selling out during the quarter.
  • NEA Management Company sold 207 Avalo Therapeutics shares in Q4 2017, an estimated $506K.
  • NEA Management Company first reported a position in Avalo Therapeutics in Q4 2015 and held it in 8 quarters.
  • NEA Management Company's Avalo Therapeutics position peaked at $2.52M in Q3 2016.
  • 16 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2017.

Based on NEA Management Company's 13F filing for Q4 2017, filed 8 Feb 2018.